Beyond Investment in Research: What COVID-19 Policymakers Can Learn from the HIV/Aids Epidemic

COVID-19 has strained the FDA to quickly evaluate new drugs and vaccines. But the tension between urgency and safety is not new—Can COVID-19 policymakers learn from the HIV epidemic? I trace the FDA’s history and offer a path toward transparency and trust: